Literature DB >> 24978876

Patent foramen ovale treatment strategy: an Italian large prospective study.

Brunilda Alushi1, Luigi Biasco, Fulvio Orzan, Pierluigi Omedé, Filippo Sciuto, Claudio Moretti, Riccardo Belli, Gianfranco Defilippi, Giulia Barisone, Paolo Cerrato, Fiorenzo Gaita.   

Abstract

AIM: There is still controversy regarding the benefit of percutaneous closure of patent foramen ovale (PFO) among patients with cryptogenic stroke. Here we aimed to evaluate the factors associated with treatment choice and predictors of adverse events in patients with cryptogenic stroke or transient ischemic attack (TIA) and PFO.
METHODS: Of 418 consecutive patients with PFO and cryptogenic stroke or TIA, 262 underwent percutaneous PFO closure, whereas 156 were medically treated. Multivariable logistic regression models were developed to evaluate factors influencing the treatment strategy and predictors of outcome, a composite of stroke, TIA or all-cause mortality.
RESULTS: Patients with large interatrial right-to-left shunt were more likely treated with percutaneous closure [odds ratio (OR) = 4.79, 95% confidence interval (2.73-8.42); P < 0.0001], whereas those with multiple cerebrovascular accident (CVA) risk factors were more likely treated medically [OR = 0.15 (0.03-0.60); P = 0.023]. Age greater than 55 years [OR = 2.70 (1.05-6.88); P = 0.04], previous CVAs [OR = 2.49 (1.03-6.02); P = 0.02] and atrial septal aneurism [ASA, OR = 2.64 (1.09-6.39); P = 0.02], but not percutaneous closure of PFO [OR = 1.10 (0.44-2.74); P = 0.81], were independent predictors of outcome.
CONCLUSION: Among patients with cryptogenic stroke and PFO, the presence of large interatrial right-to-left shunt and multiple CVA risk factors influenced the treatment choice. Older age, multiple previous CVAs and ASA, but not PFO closure, independently predicted the composite outcome of cryptogenic stroke, TIA or all-cause mortality.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24978876     DOI: 10.2459/JCM.0000000000000138

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  5 in total

Review 1.  Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials.

Authors:  Brunilda Alushi; Alexander Lauten; Salvatore Cassese; Roisin Colleran; Stefanie Schüpke; Himanshu Rai; Heribert Schunkert; Bernhard Meier; Ulf Landmesser; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2018-04-11       Impact factor: 5.460

Review 2.  Patent Foramen Ovale and Stroke-Current Status.

Authors:  Oh Young Bang; Mi Ji Lee; Sookyung Ryoo; Suk Jae Kim; Ji Won Kim
Journal:  J Stroke       Date:  2015-09-30       Impact factor: 6.967

3.  Association of Left Atrial Enlargement with Cortical Infarction in Subjects with Patent Foramen Ovale.

Authors:  Mi Ji Lee; Sung-Ji Park; Chang Hyo Yoon; Ji-Won Hwang; Sookyung Ryoo; Suk Jae Kim; Gyeong-Moon Kim; Chin-Sang Chung; Kwang Ho Lee; Oh Young Bang
Journal:  J Stroke       Date:  2016-09-30       Impact factor: 6.967

4.  Percutaneous closure versus medical therapy for stroke with patent foramen Ovale: a systematic review and meta-analysis.

Authors:  Xin-Lin Zhang; Li-Na Kang; Lian Wang; Biao Xu
Journal:  BMC Cardiovasc Disord       Date:  2018-03-02       Impact factor: 2.298

Review 5.  Patent foramen ovale and atrial fibrillation as causes of cryptogenic stroke: is treatment with surgery superior to device closure and anticoagulation? A review of the literature.

Authors:  Thomas Kjeld; Tem S Jørgensen; Gitte Fornitz; Jan Roland; Henrik C Arendrup
Journal:  Acta Radiol Open       Date:  2018-08-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.